Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 07'th Nov 2024
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG (RHHBY) or AbbVie (ABBV). But which of these two stocks offers value investors a bet
Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
08:00am, Thursday, 07'th Nov 2024
Last Year, BOTOX® Cosmetic Day Set the Record for the Most BOTOX® Cosmetic Gift Cards Sold in a Single Day1 This Year, the Excitement Continues with New Offers to Refer a Friend Plus the Best-Selli
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
10:05am, Tuesday, 05'th Nov 2024
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
07:15am, Monday, 04'th Nov 2024
The story with AbbVie NYSE: ABBV in 2024 is that it fell off a patent cliff but survived. It survived and continues to thrive because of its strengths in its core immunology portfolio and diversificat
5 Stocks That Recently Announced Dividend Hikes
08:46am, Friday, 01'st Nov 2024
Investors may keep a tab on stocks like COP, BERY, HII, ABBV and ASB, which have lately hiked their dividend payments.
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. a
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
05:30am, Thursday, 31'st Oct 2024
It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.
AbbVie: 3 Positives From The Earnings Report
06:25pm, Wednesday, 30'th Oct 2024
It is no surprise investors have responded positively to AbbVie's latest results considering revenue growth, earnings outlook upgrade, and dividend increase. The company also has growth catalysts in p
AbbVie Inc. (ABBV) Q3 2024 Earnings Call Transcript
02:26pm, Wednesday, 30'th Oct 2024
AbbVie Inc. (NYSE:ABBV ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Robert A. Michael - C hief Executive Off
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View
01:05pm, Wednesday, 30'th Oct 2024
ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.
Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics
11:31am, Wednesday, 30'th Oct 2024
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Stre
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
10:17am, Wednesday, 30'th Oct 2024
On Wednesday, AbbVie Inc. ABBV reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92.
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
09:51am, Wednesday, 30'th Oct 2024
AbbVie (ABBV) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.95 per share a year ago.
AbbVie Stock Rises After Earnings Beat, Dividend Hike
08:34am, Wednesday, 30'th Oct 2024
The drug maker increased dividend by 5.8% to $1.64 per share.
AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq
07:52am, Wednesday, 30'th Oct 2024
AbbVie raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings
